Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D475/00—Heterocyclic compounds containing pteridine ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D473/00—Heterocyclic compounds containing purine ring systems
  • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
  • C07D473/28—Oxygen atom

Definitions

• the invention relates to a process for preparing fused piperazin-2-one derivatives of general formula (I)
• Pteridinone derivatives are known from the prior art as active substances with an antiproliferative activity.
• WO 03/020722 describes the use of dihydropteridinone derivatives for the treatment of tumoral diseases and processes for preparing them.
• 7,8-Dihydro-5H-pteridin-6-one derivatives of formula (I) are important intermediate products in the synthesis of these active substances. Up till now they have been prepared using methods involving reduction of nitro compounds of formula (II) below, which led to strongly coloured product mixtures and required laborious working up and purification processes.
• WO 96/36597 describes the catalytic hydrogenation of nitro compounds using noble metal catalysts with the addition of a vanadium compound, while disclosing as end products free amines, but no lactams.
• the aim of the present invention is to provide an improved process for preparing compounds of formula (I), particularly 7,8-dihydro-5H-pteridin-6-one derivatives.
• the present invention solves the problem outlined above by the method of synthesising compounds of formula (I) described hereinafter.
• the invention thus relates to a process for preparing compounds of general formula I
• a 1 and A 2 which may be identical or different represent —CH ⁇ or —N ⁇ , preferably —N ⁇ , in which a compound of formula II
• the hydrogenation of the compound of formula II is carried out directly in the presence of the hydrogenation catalyst and the copper, iron or vanadium compound to form the compound of formula I.
• first of all the intermediate product of formula III is obtained, which may optionally be isolated,
• the hydrogenation catalyst is selected from the group consisting of rhodium, ruthenium, iridium, platinum, palladium and nickel, preferably platinum, palladium and Raney nickel. Platinum is particularly preferred. Platinum may be used in metallic form or oxidised form as platinum oxide on carriers such as e.g. activated charcoal, silicon dioxide, aluminium oxide, calcium carbonate, calcium phosphate, calcium sulphate, barium sulphate, titanium dioxide, magnesium oxide, iron oxide, lead oxide, lead sulphate or lead carbonate and optionally additionally doped with sulphur or lead.
• the preferred carrier material is activated charcoal, silicon dioxide or aluminium oxide.
• Preferred copper compounds are compounds in which copper assumes oxidation states I or II, for example the halides of copper such as e.g. CuCl, CuCl 2 , CuBr, CuBr 2 , CuI or CuSO 4 .
• Preferred iron compounds are compounds wherein iron assumes oxidation states II or III, for example the halides of iron such as e.g. FeCl 2 , FeCl 3 , FeBr 2 , FeBr 3 , FeF 2 or other iron compounds such as e.g. FeSO 4 , FePO 4 or Fe(acac) 2 .
• Preferred vanadium compounds are compounds wherein vanadium assumes the oxidation states 0, II, III, IV or V, for example inorganic or organic compounds or complexes such as e.g. V 2 O 3 , V 2 O 5 , V 2 O 4 , Na 4 VO 4 , NaVO 3 , NH 4 VO 3 , VOCl 2 , VOCl 3 , VOSO 4 , VCl 2 , VCl 3 , vanadium oxobis(1-phenyl-1,3-butanedionate), vanadium oxotriisopropoxide, vanadium(III)acetylacetonate [V(acac) 3 ] or vanadium(IV)oxyacetylacetonate [VO(acac) 2 ]. Vanadium(IV)oxyacetylacetonate [VO(acac) 2 ] is particularly preferred.
• the copper, iron or vanadium compound may be used either directly at the start of the hydrogenation or after the formation of the intermediate of formula (III), as preferred.
• the amount of added hydrogenation catalyst is between 0.1 and 10 wt.-% based on the compound of formula (II) used.
• a process wherein the reaction is carried out in a solvent selected from the group consisting of dipolar, aprotic solvents, for example dimethylformamide, dimethylacetamide, N-methylpyrrolidinone, dimethylsulphoxide or sulpholane; alcohols, for example methanol, ethanol, 1-propanol, 2-propanol, the various isomeric alcohols of butane and pentane; ethers, for example diethyl ether, methyl-tert.-butylether, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane or dimethoxyethane; esters, for example ethyl acetate, 2-propylacetate or 1-butylacetate; ketones, for example acetone, methylethylketone or methylisobutylketone; carboxylic acids, for example acetic acid; apolar solvents, for example toluene, xylene, cyclol
• reaction temperature is between 0° C. and 150° C., preferably between 20° C. and 100° C.
• the invention further relates to a compound of formula (III)
• R 1 to R 5 may have the stated meaning.
• Preferred compounds of formula (III) are those wherein A 1 and A 2 are identical and denote —N ⁇ .
• the reactions are worked up by conventional methods e.g. by extractive purification steps or precipitation and crystallisation methods.
• the compounds according to the invention may be present in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with acids—such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
• acids such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.
• alkyl groups including those which are part of other groups, are branched and unbranched alkyl groups with 1 to 12 carbon atoms, preferably 1-6, particularly preferably 1-4 carbon atoms, such as for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl.
• propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl include all the possible isomeric forms.
• propyl includes the two isomeric groups n-propyl and iso-propyl
• butyl includes n-butyl, isobutyl, sec. butyl and tert.-butyl
• pentyl includes isopentyl, neopentyl etc.
• one or more hydrogen atoms may optionally be replaced by other groups.
• these alkyl groups may be substituted by fluorine. It is also possible for all the hydrogen atoms of the alkyl group to be replaced.
• alkyl bridges are branched and unbranched alkyl groups with 2 to 5 carbon atoms, for example ethylene, propylene, isopropylene, n-butylene, iso-butyl, sec. butyl and tert.-butyl etc. bridges. Particularly preferred are ethylene, propylene and butylene bridges.
• alkyl bridges 1 to 2 C atoms may optionally be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulp r.
• alkenyl groups are branched and unbranched alkylene groups with 2 to 12 carbon atoms, preferably 2-6 carbon atoms, particularly preferably 2-3 carbon atoms, provided that they have at least one double bond.
• alkenyl groups include those which are part of other groups
• alkenyl groups are branched and unbranched alkylene groups with 2 to 12 carbon atoms, preferably 2-6 carbon atoms, particularly preferably 2-3 carbon atoms, provided that they have at least one double bond.
• alkenyl groups are branched and unbranched alkylene groups with 2 to 12 carbon atoms, preferably 2-6 carbon atoms, particularly preferably 2-3 carbon atoms, provided that they have at least one double bond.
• the above-mentioned designations propenyl, butenyl etc. include all the possible isomeric forms.
• butenyl includes 1-butenyl, 2-butenyl, 3-butenyl, 1 -methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl and 1-ethyl-1-ethenyl.
• one or more hydrogen atoms may optionally be replaced by other groups.
• these alkyl groups may be substituted by the halogen atom fluorine. It is also possible for all the hydrogen atoms of the alkenyl group to be replaced.
• alkynyl groups are branched and unbranched alkynyl groups with 2 to 12 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.
• one or more hydrogen atoms may optionally be replaced by other groups.
• these alkyl groups may be fluorosubstituted. It is also possible for all the hydrogen atoms of the alkynyl group to be replaced.
• aryl denotes an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, preferably phenyl, which, unless otherwise described, may for example carry one or more of the following substituents: OH, NO 2 , CN, OMe, —OCHF 2 , —OCF 3 , halogen, preferably fluorine or chlorine, C 1 -C 10 -alkyl, preferably C 1 -C 5 -alkyl, preferably C 1 -C 3 -alkyl, particularly preferably methyl or ethyl, —O—C 1 -C 3 -alkyl, preferably —O-methyl or —O-ethyl, —COOH, —COO—C 1 -C 4 -alkyl, preferably —O-methyl or —O-ethyl, —CONH 2 .
• cycloalkyl groups are cycloalkyl groups with 3-12 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, while each of the above-mentioned cycloalkyl groups may optionally also carry one or more substituents, for example: OH, NO 2 , CN, OMe, —OCHF 2 , —OCF 3 or halogen, preferably fluorine or chlorine, C 1 -C 10 -alkyl, preferably C 1 -C 5 -alkyl, preferably C 1 -C 3 -alkyl, particularly preferably methyl or ethyl, —O—C 1 -C 3 -alkyl, preferably —O-methyl or —O-ethyl, —
• cycloalkenyl groups are cycloalkyl groups with 3-12 carbon atoms, which have at least one double bond, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, preferably cyclopropenyl, cyclopentenyl or cyclohexenyl, while each of the above-mentioned cycloalkenyl groups may optionally also carry one or more substituents.
• ⁇ O denotes an oxygen atom linked by a double bond.
• heterocycloalkyl groups are, unless otherwise described in the definitions, 3- to 12-membered, preferably 5-, 6- or 7-membered, saturated or unsaturated heterocycles, which may contain nitrogen, oxygen or sulphur as heteroatoms, for example tetrahydrofuran, tetrahydrofuranone, ⁇ -butyrolactone, ⁇ -pyran, ⁇ -pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxazine, tetrahydro-o
• polycycloalkyl groups are optionally substituted, bi-, tri-, tetra- or pentacyclic cycloalkyl groups, for example pinane, 2,2,2-octane, 2,2,1-heptane or adamantane.
• polycycloalkenyl groups are optionally bridged and/or substituted, 8- membered bi-, tri-, tetra- or pentacyclic cycloalkenyl groups, preferably bicycloalkenyl or tricycloalkenyl groups, if they contain at least one double bond, for example norbornene.
• spiroalkyl groups are optionally substituted spirocyclic C 5 -C 12 alkyl groups.
• Halogen generally denotes fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, particularly preferably chlorine.
• the substituent R 1 may represent a group selected from the group consisting of chlorine, fluorine, bromine, methanesulphonyl, ethanesulphonyl, trifluoromethanesulphonyl and para-toluenesulphonyl, preferably chlorine.
• the substituent R 2 may represent hydrogen or C 1 -C 3 -alkyl, preferably hydrogen.
• the substituent R 3 may represent hydrogen
• the substituents R 4 , R 5 may be identical or different and may represent hydrogen
• a 1 and A 2 which may be identical or different represent —CH ⁇ or —N ⁇ , preferably —N ⁇ .
• R 6 may represent a C 1 -C 4 -alkyl, preferably methyl or ethyl.
• the compound of formula (II) may be prepared according to methods known from the literature, for example analogously to the syntheses described in WO 03/020722.

Abstract

Disclosed are processes for the preparation of fused piperazin-2-one derivatives of general formula (I)

wherein the groups R¹ to R⁵, A₁ and A₂ have the meanings given in the claims and in the description, particularly the preparation of 7,8-dihydro-5H-pteridin-6-one derivatives and intermediates thereof.

Description

APPLICATION DATA

This application claims priority to German application DE 10 2004 058 337.4 filed Dec. 2, 2004.

The invention relates to a process for preparing fused piperazin-2-one derivatives of general formula (I)

wherein the groups R¹ to R⁵ have the meanings given in the claims and specification, particularly a process for preparing 7,8-dihydro-5H-pteridin-6-one derivatives.

BACKGROUND TO THE INVENTION

Pteridinone derivatives are known from the prior art as active substances with an antiproliferative activity. WO 03/020722 describes the use of dihydropteridinone derivatives for the treatment of tumoral diseases and processes for preparing them.

7,8-Dihydro-5H-pteridin-6-one derivatives of formula (I) are important intermediate products in the synthesis of these active substances. Up till now they have been prepared using methods involving reduction of nitro compounds of formula (II) below, which led to strongly coloured product mixtures and required laborious working up and purification processes.

WO 96/36597 describes the catalytic hydrogenation of nitro compounds using noble metal catalysts with the addition of a vanadium compound, while disclosing as end products free amines, but no lactams.

The aim of the present invention is to provide an improved process for preparing compounds of formula (I), particularly 7,8-dihydro-5H-pteridin-6-one derivatives.

DETAILED DESCRIPTION OF THE INVENTION

The present invention solves the problem outlined above by the method of synthesising compounds of formula (I) described hereinafter.

The invention thus relates to a process for preparing compounds of general formula I

• wherein
• R¹ denotes a group selected from the group consisting of chlorine, fluorine, bromine, methanesulphonyl, ethanesulphonyl, trifluoromethanesulphonyl, paratoluenesulphonyl, CH₃S(═O)— and phenylS(═O)—
• R² denotes hydrogen or C₁-C₃-alkyl,
• R³ denotes hydrogen or a group selected from the group consisting of optionally substituted C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl, C₂-C₁₂-alkynyl and C₆-C₁₄-aryl, or a group selected from the group consisting of optionally substituted and/or bridged C₃-C₁₂-Cycloalkyl, C₃-C₁₂-cycloalkenyl, C₇-C₁₂-polycycloalkyl, C₇-C₁₂-polycycloalkenyl, C₅-C₁₂-spirocycloalkyl and saturated or unsaturated C₃-C₁₂-heterocycloalkyl, which contains 1 to 2 heteroatoms,
• R⁴, R⁵ which may be identical or different denote hydrogen or optionally substituted C₁-C₆-alkyl, or
• R⁴ and R⁵ together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, or
• R⁴ and R³ or R⁵ and R³ together denote a saturated or unsaturated C₃-C₄-alkyl bridge, which may optionally contain 1 heteroatom,
  and

A₁ and A₂ which may be identical or different represent —CH═ or —N═, preferably —N═, in which a compound of formula II

wherein

• R¹-R⁵ and A₁, A₂ have the stated meaning and
• R⁶ denotes C₁-C₄-alkyl,
• a) is hydrogenated with hydrogen in the presence of a hydrogenation catalyst and
• b) a copper, iron or vanadium compound is added,
  in which steps a) and b) may take place simultaneously or successively.

In a preferred process, the hydrogenation of the compound of formula II is carried out directly in the presence of the hydrogenation catalyst and the copper, iron or vanadium compound to form the compound of formula I.

In a particularly preferred process, after the first hydrogenation step a), first of all the intermediate product of formula III is obtained, which may optionally be isolated,

and is then further reduced in the presence of a hydrogenation catalyst and a copper, iron or vanadium compound to form a compound of formula I

Also preferred is a process in which the hydrogenation catalyst is selected from the group consisting of rhodium, ruthenium, iridium, platinum, palladium and nickel, preferably platinum, palladium and Raney nickel. Platinum is particularly preferred. Platinum may be used in metallic form or oxidised form as platinum oxide on carriers such as e.g. activated charcoal, silicon dioxide, aluminium oxide, calcium carbonate, calcium phosphate, calcium sulphate, barium sulphate, titanium dioxide, magnesium oxide, iron oxide, lead oxide, lead sulphate or lead carbonate and optionally additionally doped with sulphur or lead. The preferred carrier material is activated charcoal, silicon dioxide or aluminium oxide.

Preferred copper compounds are compounds in which copper assumes oxidation states I or II, for example the halides of copper such as e.g. CuCl, CuCl₂, CuBr, CuBr₂, CuI or CuSO₄. Preferred iron compounds are compounds wherein iron assumes oxidation states II or III, for example the halides of iron such as e.g. FeCl₂, FeCl₃, FeBr₂, FeBr₃, FeF₂ or other iron compounds such as e.g. FeSO₄, FePO₄ or Fe(acac)₂.

Preferred vanadium compounds are compounds wherein vanadium assumes the oxidation states 0, II, III, IV or V, for example inorganic or organic compounds or complexes such as e.g. V₂O₃, V₂O₅, V₂O₄, Na₄VO₄, NaVO₃, NH₄VO₃, VOCl₂, VOCl₃, VOSO₄, VCl₂, VCl₃, vanadium oxobis(1-phenyl-1,3-butanedionate), vanadium oxotriisopropoxide, vanadium(III)acetylacetonate [V(acac)₃] or vanadium(IV)oxyacetylacetonate [VO(acac)₂]. Vanadium(IV)oxyacetylacetonate [VO(acac)₂] is particularly preferred.

The copper, iron or vanadium compound may be used either directly at the start of the hydrogenation or after the formation of the intermediate of formula (III), as preferred.

Also preferred is a process wherein the amount of added hydrogenation catalyst is between 0.1 and 10 wt.-% based on the compound of formula (II) used.

Also preferred is a process wherein the amount of copper, iron or vanadium compound used is between 0.01 and 10 wt.-% based on the compound of formula (II) used.

Also preferred is a process wherein the reaction is carried out in a solvent selected from the group consisting of dipolar, aprotic solvents, for example dimethylformamide, dimethylacetamide, N-methylpyrrolidinone, dimethylsulphoxide or sulpholane; alcohols, for example methanol, ethanol, 1-propanol, 2-propanol, the various isomeric alcohols of butane and pentane; ethers, for example diethyl ether, methyl-tert.-butylether, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane or dimethoxyethane; esters, for example ethyl acetate, 2-propylacetate or 1-butylacetate; ketones, for example acetone, methylethylketone or methylisobutylketone; carboxylic acids, for example acetic acid; apolar solvents, for example toluene, xylene, cyclohexane or methylcyclohexane, as well as acetonitrile, methylene chloride and water. The solvents may also be used as mixtures.

Also preferred is a process wherein the reaction temperature is between 0° C. and 150° C., preferably between 20° C. and 100° C.

Also preferred is a process wherein the hydrogen pressure is 1 bar to 100 bar.

The invention further relates to a compound of formula (III)

wherein R¹ to R⁵ may have the stated meaning.

Preferred compounds of formula (III) are those wherein A₁ and A₂ are identical and denote —N═.

The reactions are worked up by conventional methods e.g. by extractive purification steps or precipitation and crystallisation methods.

The compounds according to the invention may be present in the form of the individual optical isomers, mixtures of the individual enantiomers, diastereomers or racemates, in the form of the tautomers as well as in the form of the free bases or the corresponding acid addition salts with acids—such as for example acid addition salts with hydrohalic acids, for example hydrochloric or hydrobromic acid, or organic acids, such as for example oxalic, fumaric, diglycolic or methanesulphonic acid.

Examples of alkyl groups, including those which are part of other groups, are branched and unbranched alkyl groups with 1 to 12 carbon atoms, preferably 1-6, particularly preferably 1-4 carbon atoms, such as for example: methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl. Unless otherwise stated, the above-mentioned designations propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl and dodecyl include all the possible isomeric forms. For example the term propyl includes the two isomeric groups n-propyl and iso-propyl, the term butyl includes n-butyl, isobutyl, sec. butyl and tert.-butyl, the term pentyl includes isopentyl, neopentyl etc.

In the above-mentioned alkyl groups one or more hydrogen atoms may optionally be replaced by other groups. For example these alkyl groups may be substituted by fluorine. It is also possible for all the hydrogen atoms of the alkyl group to be replaced.

Examples of alkyl bridges, unless otherwise stated, are branched and unbranched alkyl groups with 2 to 5 carbon atoms, for example ethylene, propylene, isopropylene, n-butylene, iso-butyl, sec. butyl and tert.-butyl etc. bridges. Particularly preferred are ethylene, propylene and butylene bridges. In the above-mentioned alkyl bridges 1 to 2 C atoms may optionally be replaced by one or more heteroatoms selected from among oxygen, nitrogen or sulp^r.

Examples of alkenyl groups (including those which are part of other groups) are branched and unbranched alkylene groups with 2 to 12 carbon atoms, preferably 2-6 carbon atoms, particularly preferably 2-3 carbon atoms, provided that they have at least one double bond. The following are mentioned by way of example: ethenyl, propenyl, butenyl, pentenyl etc. Unless otherwise stated, the above-mentioned designations propenyl, butenyl etc. include all the possible isomeric forms. For example the term butenyl includes 1-butenyl, 2-butenyl, 3-butenyl, 1 -methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl and 1-ethyl-1-ethenyl.

In the above-mentioned alkenyl groups, unless otherwise described, one or more hydrogen atoms may optionally be replaced by other groups. For example these alkyl groups may be substituted by the halogen atom fluorine. It is also possible for all the hydrogen atoms of the alkenyl group to be replaced.

Examples of alkynyl groups (including those which are part of other groups) are branched and unbranched alkynyl groups with 2 to 12 carbon atoms, provided that they have at least one triple bond, for example ethynyl, propargyl, butynyl, pentynyl, hexynyl etc., preferably ethynyl or propynyl.

In the above-mentioned alkynyl groups, unless otherwise described, one or more hydrogen atoms may optionally be replaced by other groups. For example these alkyl groups may be fluorosubstituted. It is also possible for all the hydrogen atoms of the alkynyl group to be replaced.

The term aryl denotes an aromatic ring system with 6 to 14 carbon atoms, preferably 6 or 10 carbon atoms, preferably phenyl, which, unless otherwise described, may for example carry one or more of the following substituents: OH, NO₂, CN, OMe, —OCHF₂, —OCF₃, halogen, preferably fluorine or chlorine, C₁-C₁₀-alkyl, preferably C₁-C₅-alkyl, preferably C₁-C₃-alkyl, particularly preferably methyl or ethyl, —O—C₁-C₃-alkyl, preferably —O-methyl or —O-ethyl, —COOH, —COO—C₁-C₄-alkyl, preferably —O-methyl or —O-ethyl, —CONH₂.

Examples of cycloalkyl groups are cycloalkyl groups with 3-12 carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl, preferably cyclopropyl, cyclopentyl or cyclohexyl, while each of the above-mentioned cycloalkyl groups may optionally also carry one or more substituents, for example: OH, NO₂, CN, OMe, —OCHF₂, —OCF₃ or halogen, preferably fluorine or chlorine, C₁-C₁₀-alkyl, preferably C₁-C₅-alkyl, preferably C₁-C₃-alkyl, particularly preferably methyl or ethyl, —O—C₁-C₃-alkyl, preferably —O-methyl or —O-ethyl, —COOH, —COO—C₁-C₄-alkyl, preferably —COO-methyl or —COO-ethyl or —CONH₂. Particularly preferred substituents of the cycloalkyl groups are ═O, OH, methyl or F.

Examples of cycloalkenyl groups are cycloalkyl groups with 3-12 carbon atoms, which have at least one double bond, for example cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, preferably cyclopropenyl, cyclopentenyl or cyclohexenyl, while each of the above-mentioned cycloalkenyl groups may optionally also carry one or more substituents.

“═O” denotes an oxygen atom linked by a double bond.

Examples of heterocycloalkyl groups are, unless otherwise described in the definitions, 3- to 12-membered, preferably 5-, 6- or 7-membered, saturated or unsaturated heterocycles, which may contain nitrogen, oxygen or sulphur as heteroatoms, for example tetrahydrofuran, tetrahydrofuranone, γ-butyrolactone, α-pyran, γ-pyran, dioxolane, tetrahydropyran, dioxane, dihydrothiophene, thiolane, dithiolane, pyrroline, pyrrolidine, pyrazoline, pyrazolidine, imidazoline, imidazolidine, tetrazole, piperidine, pyridazine, pyrimidine, pyrazine, piperazine, triazine, tetrazine, morpholine, thiomorpholine, diazepan, oxazine, tetrahydro-oxazinyl, isothiazole and pyrazolidine, preferably morpholine, pyrrolidine, piperidine or piperazine, while the heterocycle may optionally carry substituents, for example C₁-C₄-alkyl, preferably methyl, ethyl or propyl.

Examples of polycycloalkyl groups are optionally substituted, bi-, tri-, tetra- or pentacyclic cycloalkyl groups, for example pinane, 2,2,2-octane, 2,2,1-heptane or adamantane. Examples of polycycloalkenyl groups are optionally bridged and/or substituted, 8- membered bi-, tri-, tetra- or pentacyclic cycloalkenyl groups, preferably bicycloalkenyl or tricycloalkenyl groups, if they contain at least one double bond, for example norbornene.

Examples of spiroalkyl groups are optionally substituted spirocyclic C₅-C₁₂ alkyl groups.

Halogen generally denotes fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, particularly preferably chlorine.

The substituent R¹ may represent a group selected from the group consisting of chlorine, fluorine, bromine, methanesulphonyl, ethanesulphonyl, trifluoromethanesulphonyl and para-toluenesulphonyl, preferably chlorine.

The substituent R² may represent hydrogen or C₁-C₃-alkyl, preferably hydrogen.

The substituent R³ may represent hydrogen,

• • or a group selected from the group consisting of optionally substituted C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl, C₂-C₁₂-alkynyl, and C₆-C₁₄-aryl, preferably phenyl,
  • or a group selected from the group consisting of optionally substituted and/or bridged C₃-C₁₂-Cycloalkyl, preferably cyclopentyl, C₃-C_12-cycloalkenyl, C₇-C₁₂-polycycloalkyl, C₇-C₁₂-polycycloalkenyl, C₅-C₁₂-spirocycloalkyl and saturated or unsaturated C₃-C₁₂-heterocycloalkyl, which contains 1 to 2 heteroatoms.

The substituents R⁴, R⁵ may be identical or different and may represent hydrogen,

• • or optionally substituted C₁-C₆-alkyl,
  • or R⁴ and R⁵ together represent a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms,
  • or R⁴ and R³ or R⁵ and R³ together represent a saturated or unsaturated C₃-C₄-alkyl bridge, which may optionally contain 1 heteroatom.

A₁ and A₂ which may be identical or different represent —CH═ or —N═, preferably —N═.

R⁶ may represent a C₁-C₄-alkyl, preferably methyl or ethyl.

The compound of formula (II) may be prepared according to methods known from the literature, for example analogously to the syntheses described in WO 03/020722.

The compounds of general formula (I) may be prepared inter alia analogously to the following examples of synthesis. These Examples are, however, intended only as examples of procedures to illustrate the invention, without restricting it to their content. The general synthesis is shown in Scheme (1).

Synthesis of (7R)-2-chloro-8-cyclopentyl-7-ethyl-5-hydroxy-7,8-dihydro-5H-pteridin-6-one

30 g (84.2 mmol) of 1 are dissolved in 300 ml tetrahydrofuran and 3 g Pt/C (5%) are added. The reaction mixture is hydrogenated for 5 h at 35° C. and a hydrogen pressure of 4 bar. The catalyst is filtered off and washed with approx. 30 ml of tetrahydrofuran. The filtrate is concentrated by evaporation under reduced pressure. 25.6 g of product 2 are obtained as a yellow solid.

¹H-NMR (400 MHZ) (DMSO_d6): δ 11.05 (bs 1H); 7.85 (s 1H); 4.47-4.45 (dd 1H); 4.16-4.08 (t 1H); 1.95-1.67 (m 10H); 0.80-0.73 (t 3H)

Synthesis of (7R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-5H-pteridin-6-one

5.22 g (17.6 mmol) of 2 are dissolved in 55 ml of tetrahydrofuran. 520 mg Pt-C (5%) and 250 mg vanadium(IV)oxyacetylacetonate are added. The reaction mixture is hydrogenated for 6 hours at 20° C. and a hydrogen pressure of 4 bar. The catalyst is filtered off and washed with approx. 15 ml of tetrahydrofuran. The filtrate is concentrated by evaporation under reduced pressure.

5.0 g of product 3 are obtained as a yellow powder.

¹H-NMR (400 MHz) (DMSO_d6): δ 11.82 (bs 1H); 7.57 (s 1H); 4.24-4.21 (dd 1H); 4.17-4.08 (m 1H); 1.97-1.48 (m 10H); 0.80-0.77 (t 3H).

Synthesis of: (7R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-5H-pteridin-6-one

70 g Pt/C (5%)are added to a solution of 700 g (1.96 mol) of 1 in 700 ml of tetrahydrofuran. The reaction mixture is hydrogenated for 2.5 hours at 35° C. and a hydrogen pressure of 4 bar until the hydrogen uptake has stopped. The autoclave is opened and 35 g vanadium(IV)oxyacetylacetonate are added. The mixture is hydrogenated for a further 2.5 hours at 35° C. and a hydrogen pressure of 4 bar. It is filtered and the residue is washed with tetrahydrofuran. The filtrate is concentrated by evaporation under reduced pressure. The residue is dissolved in 2.75 L acetone and precipitated by the addition of an equal amount of demineralised water. The solid is suction filtered and washed with an acetone/water mixture (1:1), then with tert.-butylmethylether. After drying 551 g of product 3 are obtained.

Synthesis of: (7R)-2-chloro-8-cyclopentyl-7-ethyl-7,8-dihydro-5H-pteridin-6-one

30 g (84 mmol) of 1 are dissolved in 300 ml of tetrahydrofuran. 3 g Pt/C (5%) and 1.5 g vanadium(IV)oxyacetylacetonate are added. The reaction mixture is hydrogenated for 24 hours at 35° C. and a hydrogen pressure of 4 bar until the reaction is complete. It is filtered, the residue is washed with tetrahydrofuran and the filtrate is concentrated by evaporation under reduced pressure. The residue is dissolved in 118 ml acetone and precipitated by the addition of an equal amount of demineralised water. The solid is suction filtered and washed with an acetone/water mixture (1:1) and then with tert.-butylmethylether. After drying 18 g of product 3 are obtained.

Synthesis of: (7R)-2-chloro-7-ethyl-8-isopropyl-7,8-dihydro-5H-pteridin-6-one

10 g (316 mmol) of 4 are dissolved in 800 ml of tetrahydrofuran and 200 ml isopropanol. 10 g Pt/C (5%) and 5 g vanadium(IV)oxyacetylacetonate are added. The reaction mixture is hydrogenated for 24 hours at 35° C. and a hydrogen pressure of 4 bar until the reaction is complete. It is filtered and the filtrate is evaporated down until crystallisation sets in. 150 ml isopropanol are added and the suspension is heated to 70-80° C. until fully dissolved. After the addition of 600 ml demineralised water the product is brought to crystallisation. It is suction filtered and washed with demineralised water. After drying 68 g of product 5 are obtained.

¹H NMR (400 MHz) (DMSO_d6): δ 10.81 (bs 1H); 7.56 (s 1H); 4.37-4.24 (m 2H); 1.89-1.65 (m 2H); 1.34-1.31 (m 6H); 0.80-0.73 (t 3H)

Claims (16)

1. A Process for preparing compounds of the formula I

wherein

R¹ denotes a group selected from the group consisting of chlorine, fluorine, bromine, methanesulphonyl, ethanesulphonyl, trifluoromethanesulphonyl, para-toluenesulphonyl, CH₃S(═O)— and phenylS(═O)—,

R² denotes hydrogen or C₁-C₃-alkyl,

R³ denotes hydrogen or a group selected from the group consisting of optionally substituted C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl, C₂-C₁₂-alkynyl and C₆-C₁₄-aryl, or

a group selected from the group consisting of optionally substituted and/or bridged C₃-C₁₂-cycloalkyl, C₃-C₁₂-cycloalkenyl, C₇-C₁₂-polycycloalkyl, C₇-C₁₂-polycycloalkenyl, C₅-C₁₂-spirocycloalkyl and saturated or unsaturated C₃-C₁₂-heterocycloalkyl, which contains 1 to 2 heteroatoms,

R⁴, R⁵ which may be identical or different denote hydrogen or optionally substituted C₁-C₆-alkyl, or

R⁴ and R⁵ together denote a 2- to 5-membered alkyl bridge, which may contain 1 to 2 heteroatoms, or

R⁴ and R³ or R⁵ and R³ together denote a saturated or unsaturated C₃-C₄-alkyl bridge, which may optionally contain 1 heteroatom, and

“A1 and A2 denote —N═”, comprising

a) hydrogenating with hydrogen in the presence of a hydrogenation catalyst and a compound of formula II

wherein

R¹ to R⁵, A₁ and A₂ have the meanings given above and

R⁶ denotes C₁-C₄-alkyl, and

b) adding a copper, iron or vanadium compound,

wherein in which steps a) and b) may take place simultaneously or successively wherein step b) followed by follows step a).

2. The Process according to claim 1, wherein in step b) a copper compound is added.

3. The Process according to claim 1, wherein in step b) an iron compound is added.

4. The Process according to claim 1, wherein in step b) a vanadium compound is added.

5. The Process according to claim 1 wherein steps a) and b) are carried out successively wherein step b) follows step a).

6. The Process according to claim 5, wherein that after the first step a) the intermediate product of formula III is first obtained, which may optionally be isolated,

and after the subsequent step b) a compound of formula I is obtained.

7. The Process according to claim 1, wherein steps a) and b) are carried out simultaneously.

8. The Process according to claim 1, wherein the hydrogenation catalyst is selected from the group consisting of rhodium, ruthenium, iridium, platinum, palladium and nickel.

9. The Process according to claim 1, wherein the amount of hydrogenation catalyst added is between 0.1 and 10 wt.-%, based on the compound of formula (II) used.

10. The Process according to claim 1, wherein the amount of copper, iron or vanadium compound added is between 0.01 and 10 wt-%, based on the compound of formula (II) used.

11. The Process according to claim 1, wherein the reaction is carried out in a solvent or mixture of solvents selected from the group consisting of dipolar, aprotic solvents, alcohols, ethers, esters, carboxylic acids, apolar solvents, acetonitrile, methylene chloride and water.

12. The Process according to claim 1, wherein the reaction temperature is between 0° C. and 150° C.

13. The Process according to claim 1, wherein the hydrogen pressure is from 1 bar to 100 bar.

14. A Process for preparing compounds of the formula I

wherein

R¹ denotes a group selected from the group consisting of chlorine, fluorine, bromine, methanesulphonyl, ethanesulphonyl, trifluoromethanesulphonyl, para-toluenesulphonyl, CH₃S(═O)— and phenylS(═O)—,

R² denotes hydrogen or C₁-C₃-alkyl,

R³ denotes hydrogen or a group selected from the group consisting of optionally substituted C1-C12-alkyl, C2-C12-alkenyl, C2-C12-alkynyl C₁-C₁₂-alkyl, C₂-C₁₂-alkenyl, C₂-C₁₂-alkynyl and C₆-C₁₄-aryl, or

a group selected from the group consisting of optionally substituted and/or bridged C₃-C₁₂-cycloalkyl, C₃-C₁₂-cycloalkenyl, C₇-C₁₂-polycycloalkyl, C₇-C₁₂-polycycloalkenyl, C₅-C₁₂-spirocycloalkyl and saturated or unsaturated C₃-C₁₂-heterocycloalkyl, which contains 1 to 2 heteroatoms,

R⁴, R⁵ which may be identical or different denote hydrogen or optionally substituted C₁-C₆-alkyl, or

R⁴, R⁵ together denote a 2- to 5-membered alkyl bridge, which may contain 1 to 2 heteroatoms, or

R⁴ and R³ or R⁵ and R³ together denote a saturated or unsaturated C₃-C₄-alkyl bridge, which may optionally contain 1 heteroatom, and

A₁ and A₂ denote —N═, comprising

hydrogenating a compound of formula III with hydrogen in the presence of a hydrogenation catalyst and a copper, iron or vanadium compound

wherein

R¹ to R⁵ and A₁, A₂ have the meanings given above in this claim.

15. The Process according to claim 11, wherein the solvent or mixture of solvents is:

alcohols selected from ethanol, 1-propanol and 2-propanol,

ethers selected from diethyl ether, methyl-tert.-butylether, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane and dimethoxyethane,

esters selected from ethyl acetate, 2-propylacetate or 1-butylacetate,

acetic acid, acetonitrile, methylene chloride or water.

16. The Process according to claim 15, wherein the solvent is 2-propanol or tetrahydrofuran or mixtures thereof.

Priority Applications (1)

Applications Claiming Priority (4)

Related Parent Applications (1)

Publications (1)

Family

ID=35923724

Family Applications (9)

Family Applications Before (8)

Country Status (35)

Families Citing this family (28)

Citations (53)

Family Cites Families (4)

• 2004
  • 2004-12-02 DE DE102004058337A patent/DE102004058337A1/en not_active Withdrawn
• 2005
  • 2005-11-22 US US11/284,836 patent/US7238807B2/en not_active Ceased
  • 2005-11-29 EP EP05823799A patent/EP1819706B1/en active Active
  • 2005-11-29 JP JP2007543838A patent/JP5164574B2/en active Active
  • 2005-11-29 UY UY29233A patent/UY29233A1/en not_active Application Discontinuation
  • 2005-11-29 PL PL05823799T patent/PL1819706T3/en unknown
  • 2005-11-29 SI SI200531631T patent/SI1819706T1/en unknown
  • 2005-11-29 KR KR1020127028659A patent/KR101395591B1/en not_active IP Right Cessation
  • 2005-11-29 ES ES05823799T patent/ES2395829T3/en active Active
  • 2005-11-29 CN CN201010593286.0A patent/CN102093361B/en not_active Expired - Fee Related
  • 2005-11-29 PL PL11189691T patent/PL2436685T3/en unknown
  • 2005-11-29 SG SG201000003-2A patent/SG158848A1/en unknown
  • 2005-11-29 DK DK11189691.6T patent/DK2436685T3/en active
  • 2005-11-29 EP EP11189691.6A patent/EP2436685B1/en active Active
  • 2005-11-29 MX MX2007006549A patent/MX2007006549A/en active IP Right Grant
  • 2005-11-29 HU HUE11189691A patent/HUE027689T2/en unknown
  • 2005-11-29 RS RS20120519A patent/RS52533B/en unknown
  • 2005-11-29 NZ NZ556182A patent/NZ556182A/en not_active IP Right Cessation
  • 2005-11-29 ME MEP-2012-124A patent/ME01470B/en unknown
  • 2005-11-29 CN CN2010105934512A patent/CN102070637B/en not_active Expired - Fee Related
  • 2005-11-29 KR KR1020077015136A patent/KR101362131B1/en not_active IP Right Cessation
  • 2005-11-29 ES ES11189691.6T patent/ES2548680T3/en active Active
  • 2005-11-29 AU AU2005311308A patent/AU2005311308B2/en not_active Ceased
  • 2005-11-29 CN CN2005800406546A patent/CN101065381B/en not_active Expired - Fee Related
  • 2005-11-29 BR BRPI0518601-3A patent/BRPI0518601A2/en not_active IP Right Cessation
  • 2005-11-29 EA EA200701164A patent/EA012624B1/en not_active IP Right Cessation
  • 2005-11-29 SG SG200802431-7A patent/SG141461A1/en unknown
  • 2005-11-29 DK DK05823799.1T patent/DK1819706T3/en active
  • 2005-11-29 PT PT58237991T patent/PT1819706E/en unknown
  • 2005-11-29 UA UAA200706986A patent/UA89390C2/en unknown
  • 2005-11-29 WO PCT/EP2005/056291 patent/WO2006058876A1/en active Application Filing
  • 2005-11-29 CA CA2588857A patent/CA2588857C/en not_active Expired - Fee Related
  • 2005-11-30 MY MYPI20055607A patent/MY147459A/en unknown
  • 2005-11-30 PE PE2005001388A patent/PE20061061A1/en not_active Application Discontinuation
  • 2005-11-30 PE PE2009000418A patent/PE20090488A1/en not_active Application Discontinuation
  • 2005-12-01 TW TW094142312A patent/TWI362391B/en not_active IP Right Cessation
  • 2005-12-02 AR ARP050105040A patent/AR053100A1/en unknown
• 2007
  • 2007-04-25 ZA ZA200703368A patent/ZA200703368B/en unknown
  • 2007-05-03 NO NO20072283A patent/NO20072283L/en not_active Application Discontinuation
  • 2007-05-16 US US11/749,206 patent/US7626019B2/en active Active
  • 2007-05-16 US US11/749,210 patent/US20070213531A1/en not_active Abandoned
  • 2007-05-16 US US11/749,207 patent/US20070213534A1/en not_active Abandoned
  • 2007-05-16 US US11/749,212 patent/US20070213530A1/en not_active Abandoned
  • 2007-05-16 US US11/749,203 patent/US20070213528A1/en not_active Abandoned
  • 2007-05-16 US US11/749,208 patent/US20070219369A1/en not_active Abandoned
  • 2007-05-16 US US11/749,205 patent/US20070213529A1/en not_active Abandoned
  • 2007-05-31 IL IL183568A patent/IL183568A/en not_active IP Right Cessation
• 2008
  • 2008-04-02 HK HK08103652.5A patent/HK1113489A1/en not_active IP Right Cessation
• 2010
  • 2010-08-05 US US12/850,993 patent/USRE43115E1/en active Active
• 2011
  • 2011-11-23 HK HK11112664.7A patent/HK1158199A1/en not_active IP Right Cessation
  • 2011-11-23 HK HK11112665.6A patent/HK1158200A1/en not_active IP Right Cessation
• 2012
  • 2012-11-30 HR HRP20120980TT patent/HRP20120980T1/en unknown
  • 2012-12-12 CY CY20121101215T patent/CY1113625T1/en unknown
• 2013
  • 2013-10-09 CL CL2013002895A patent/CL2013002895A1/en unknown

Patent Citations (119)

Non-Patent Citations (72)

Also Published As

Similar Documents

Legal Events